Solute Carrier Family 7 (Cationic Amino Acid Transporter, Y+ System), Member 5 (SLC7A5) Kits ELISA

Sodium-independent, high-affinity transport of large neutral amino acids such as phenylalanine, tyrosine, leucine, arginine and tryptophan, when associated with SLC3A2/4F2hc. De plus, nous expédions SLC7A5 Anticorps (98) et SLC7A5 Protéines (3) et beaucoup plus de produits pour cette protéine.

list all ELISA KIts Gène GeneID UniProt
SLC7A5 8140 Q01650
Anti-Rat SLC7A5 SLC7A5 50719 Q63016
Anti-Souris SLC7A5 SLC7A5 20539 Q9Z127
Comment commander chez anticorps-enligne
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Commandez enligne
  • orders@anticorps-enligne.fr

Top SLC7A5 Kits ELISA sur anticorps-enligne.fr

Showing 1 out of 5 products:

Catalogue No. Reactivité Sensibilité Gamme Images Quantité Livraison Prix Détails
Humain 0.058 ng/mL 0.15 ng/mL - 10 ng/mL 96 Tests 13 to 16 Days
$736.84
Détails

SLC7A5 Kits ELISA mieux référencés

  1. Human SLC7A5 Kit ELISA pour Sandwich ELISA - ABIN417356 : Liu, Ma, Li, Yang, Liang, Yang: High expression of CD98 alters epithelial barrier functions to promote induction of airway allergy. dans Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2012 (PubMed)

Plus Kits ELISA pour SLC7A5 partenaires d'interaction

Human Solute Carrier Family 7 (Cationic Amino Acid Transporter, Y+ System), Member 5 (SLC7A5) interaction partners

  1. LAT1 was closely associated with the expression of 4F2hc and phosphorylation of the mTOR pathway. LAT1 is a significant molecular marker used to predict prognosis after surgical resection of colorectal cancer patients.

  2. The results of the present study demonstrated that SLC7A5 might be the potential candidate gene associated with central serous chorioretinopathy (CSC), indicating a previously unidentified molecular mechanism of CSC.

  3. The expression level of LAT1 was not significantly correlated with prognosis in patients with cutaneous angiosarcoma.

  4. SLC7A5 appears to play a role in the aggressive highly proliferative ER+ subtype driven by MYC and could act as a potential therapeutic target. Functional assessment is necessary to reveal the specific role played by this transporter in the ER+ highly proliferative subclass and HER2+ subclass of Breast cancer

  5. the expression of SLC7A5 on circulating monocytes from RA patients positively correlated with clinical parameters, suggesting that SLC7A5-mediated AA influx is related to inflammatory conditions.

  6. LAT1 as an independent prognostic marker is a potential molecular targeting gene to reduce chemoresistance and tumor growth in patients with PDAC, supported by our in vitro study

  7. High SLC7A5 expression is associated with gastric cancer growth and metastasis.

  8. rs4240803 impacted the expression of SLC7A5, thus contributing to the clinical response of multiple myeloma patients to melphalan therapy.

  9. JPH203 treatment significantly reduced the viability of all gastric and colon cancer cells. While LAT1 expression levels and inhibitory potencies of JPH203 on LAT1 functions were comparable among the cells, all the esophageal cells were resistant to JPH203

  10. L-type amino acid transporter 1 (LAT1) is overexpressed in the synovium of rheumatoid arthritis (RA). Suppressing the LAT1 genes by using RNA interference and the LAT inhibitor, BCH reduces the phosphorylation of mTOR and its downstream target 4EBP1, radiolabeled leucine uptake, and migration of RA FLS. Treatment of cells with Interleukin-17 stimulates the expression of LAT1.

  11. Data suggest that amino acid uptake via ASCT2/SLC1A5 is required for cell proliferation/tumor growth independently of LAT1/SLC7A5; in part, these studies were conducted in lung and colon adenocarcinoma cell lines and involved gene knockout techniques. (ASCT2/SLC1A5 = solute carrier family-1 member-5; LAT1/SLC7A5 = solute carrier family-7 member-5)

  12. review the upstream regulators of LAT1 and the downstream effects caused by the overexpression of LAT1 in cancer cells.

  13. These preclinical results show that LAT1 inhibition is a novel therapeutic approach in the context of thyroid cancers, and more interestingly in untreatable thyroid cancers.

  14. These data collectively establish that in an in vitro context, human epithelial and mesenchymal hepatocellular carcinoma cell lines adapt to ASCT2 or LAT1 knockout.

  15. SLC7A5 gene plays a role in promoting tumor development, which is regulated by the TGF-beta1 signaling pathway.

  16. LAT1 is located close to the plasma membrane in skeletal muscle fibres and in close proximity to the microvasculature. Note a greater immunoreactivity of this protein in the sarcoplasm of type II fibres, potentially supporting the greater anabolic potential in these fibres.

  17. LAT1-NAD+-SIRT1 signaling is activated in tumor tissues of patients with non-small cell lung cancer; NAD+ synthesis regulates the SIRT1-FOXO1 apoptotic pathway in response to NQO1

  18. Thus, our results indicated that lncRNA-PVT1-5 may function as a competing endogenous RNA (ceRNA) for miR-126 to promote cell proliferation by regulating the miR-126/SLC7A5 pathway, suggesting that lncRNA-PVT1-5 plays a crucial role in lung cancer progression and lncRNA-PVT1-5/miR-126/SLC7A5 regulatory network may shed light on tumorigenesis in lung cancer.

  19. Study showed that a positive [18F] FDOPA uptake in PET was associated with a minimal threshold of LAT1 expression, but did not find a linear correlation between intensity of [18F] FDOPA uptake and level of LAT1 expression.

  20. this study shows that IL-2-induced expression of CD98 is a prerequisite for NKG2D-mediated activation of NK cells

Cow (Bovine) Solute Carrier Family 7 (Cationic Amino Acid Transporter, Y+ System), Member 5 (SLC7A5) interaction partners

  1. methionine may activate the mTORC1 signaling pathway and further increase LAT1 and 4F2hc expression in the mammary gland, thus affecting milk protein synthesis

  2. Post-transcriptional de-stabilization was found in hypoxia

Mouse (Murine) Solute Carrier Family 7 (Cationic Amino Acid Transporter, Y+ System), Member 5 (SLC7A5) interaction partners

  1. Study showed that there were no significant changes in the Lat1 function at the blood-brain barrier of lipopolysaccharide-induced neuroinflammation mouse model and Alzheimer's disease transgenic mice compared to non-treated wildtype mice.

  2. Slc7a5 regulates Kv1.2 channels and modifies functional outcomes of epilepsy-linked channel mutations

  3. Study shows that capacity of kynurenine to function as an AHR ligand in immune-activated CD4+ T cells is highly regulated and dependent upon System L transporter Slc7a5 availability.

  4. these preclinical results show that LAT1 inhibition is a novel therapeutic approach in the context of thyroid cancers, and more interestingly in untreatable thyroid cancers.

  5. Results suggest that mechanical stretching promotes LAT1 expression and, consequently, amino acid uptake, leading to enhanced leucine-induced activation of protein synthesis. LAT1 has been demonstrated to be a point of crosstalk between exercise- and nutrition-induced skeletal muscle growth.

  6. These results demonstrate a novel fundamental role of LAT1 to support the protein expression of 4F2hc via a chaperone-like function in chorionic trophoblasts.

  7. results revealed that L-type amino acid transporter 1 solute carrier family 7 member 5(lat1) might play an important role in the decidual progression both in vitro and in vivo in the mouse

  8. Results demonstrate that lipopolysaccharide-induced inflammation decreases LAT1 mRNA expression at the blood-brain barrier in a very similar manner to primary thyroid hormone transporters, while changes in LAT1 protein level follow a slower kinetics.

  9. HIF-2alpha/mTORC1/SLC7A5 pathway mediates proliferation and tumor promoting properties of HIF-2alpha.

  10. expression of candidate thyroid hormone transporters Lat1, Mct8, Mct10, and Oatp1c1 in mouse cochlear development

  11. These results demonstrate that LAT-1 plays an important role in trophoblast invasion.

  12. In a neuronal cell model, y+,L and y+ transport systems are the predominant form of arginine uptake mechanisms and the transport of arginine is altered by membrane potential and redox factors.

  13. TA1 therefore appears to play a modulatory role in catecholaminergic function

  14. Expression studies of LAT-1 in developing mouse placenta show highest levels of LAT-1 mRNA in trophoblast giant cells at the time of implantation, followed by maternal decidua, ectoplacental cone and epiblast.

SLC7A5 profil antigène

Antigen Summary

Sodium-independent, high-affinity transport of large neutral amino acids such as phenylalanine, tyrosine, leucine, arginine and tryptophan, when associated with SLC3A2/4F2hc. Involved in cellular amino acid uptake. Acts as an amino acid exchanger. Involved in the transport of L-DOPA across the blood- brain barrier, and that of thyroid hormones triiodothyronine (T3) and thyroxine (T4) across the cell membrane in tissues such as placenta. Plays a role in neuronal cell proliferation (neurogenesis) in brain. Involved in the uptake of methylmercury (MeHg) when administered as the L-cysteine or D,L-homocysteine complexes, and hence plays a role in metal ion homeostasis and toxicity. Involved in the cellular activity of small molecular weight nitrosothiols, via the stereoselective transport of L- nitrosocysteine (L-CNSO) across the transmembrane. May play an important role in high-grade gliomas. Mediates blood-to-retina L- leucine transport across the inner blood-retinal barrier which in turn may play a key role in maintaining large neutral amino acids as well as neurotransmitters in the neural retina. Acts as the major transporter of tyrosine in fibroblasts.

Gene names and symbols associated with SLC7A5

  • solute carrier family 7 member 5 (SLC7A5) anticorps
  • solute carrier family 7 member 5 S homeolog (slc7a5.S) anticorps
  • solute carrier family 7 (amino acid transporter light chain, L system), member 5 (SLC7A5) anticorps
  • solute carrier family 7 member 5 (Slc7a5) anticorps
  • solute carrier family 7 (cationic amino acid transporter, y+ system), member 5 (Slc7a5) anticorps
  • 4F2LC anticorps
  • CD98 anticorps
  • D0H16S474E anticorps
  • D16S469E anticorps
  • E16 anticorps
  • hLAT1 anticorps
  • JHI-21 anticorps
  • LAT-1 anticorps
  • LAT1 anticorps
  • MPE16 anticorps
  • SLC7A5 anticorps
  • slc7a5a anticorps
  • TA1 anticorps

Protein level used designations for SLC7A5

solute carrier family 7 (cationic amino acid transporter, y+ system), member 5 , L amino acid transporter-1 , solute carrier family 7 (cationic amino acid transporter, y+ system), member 5 a , large neutral amino acids transporter small subunit 1-like , L-type amino acid transporter 1 , 4F2 LC , 4F2 light chain , CD98 light chain , integral membrane protein E16 , large neutral amino acids transporter 1 , large neutral amino acids transporter small subunit 1 , sodium-independent neutral amino acid transporter LAT1 , solute carrier family 7 member 5 , y+ system cationic amino acid transporter , 4F2LC , tumor-associated protein 1 , LAT1 light chain , blood-brain barrier large neutral amino acid transporter light chain

GENE ID SPECIES
454300 Pan troglodytes
734908 Xenopus laevis
100070633 Equus caballus
100448375 Pongo abelii
100468553 Ailuropoda melanoleuca
100134831 Sus scrofa
100218991 Taeniopygia guttata
8140 Homo sapiens
50719 Rattus norvegicus
100008844 Oryctolagus cuniculus
415832 Gallus gallus
489667 Canis lupus familiaris
282369 Bos taurus
20539 Mus musculus
Fournisseurs de qualité sélectionnés pour SLC7A5 (SLC7A5) Kits ELISA
Avez-vous cherché autre chose?